2023
Further decompensation in cirrhosis: Results of a large multicenter cohort study supporting Baveno VII statements
D’Amico G, Zipprich A, Villanueva C, Sordà J, Morillas R, Garcovich M, Retortillo M, Martinez J, Calès P, D’Amico M, Dollinger M, García-Guix M, Ballerga E, Tsochatzis E, Cirera I, Albillos A, Roquin G, Pasta L, Colomo A, Daruich J, Canete N, Boursier J, Dallio M, Gasbarrini A, Iacobellis A, Gobbo G, Merli M, Federico A, Baroni G, Pozzoni P, Addario L, Chessa L, Ridola L, Garcia-Tsao G. Further decompensation in cirrhosis: Results of a large multicenter cohort study supporting Baveno VII statements. Hepatology 2023, 79: 869-881. PMID: 37916970, DOI: 10.1097/hep.0000000000000652.Peer-Reviewed Original ResearchMulticenter cohort studyFurther decompensationLiver transplantFirst decompensationCumulative incidenceCohort studyLarge multicenter cohort studyCause-specific Cox modelsFive-year probabilityHazard ratioPrognostic weightPrognostic indicatorDecompensationCirrhosisCox modelPatientsAdvanced stageTransplantIncidenceMortalityDeathAscitesComplicationsMonthsWED-352 Gender differences in the patient-reported outcomes and perception of ascites burden amongst outpatients with decompensated cirrhosis and ascites
Wong F, Reddy K, Tandon P, Lai J, Garcia-Tsao G, O’Leary J, Biggins S, Vargas H, Thacker L, Bajaj J. WED-352 Gender differences in the patient-reported outcomes and perception of ascites burden amongst outpatients with decompensated cirrhosis and ascites. Journal Of Hepatology 2023, 78: s256. DOI: 10.1016/s0168-8278(23)00822-x.Peer-Reviewed Original Research
2022
Portal pressure reductions induced by nonselective beta‐blockers improve outcomes and decrease mortality in patients with cirrhosis with and without ascites
Turco L, García‐Tsao G. Portal pressure reductions induced by nonselective beta‐blockers improve outcomes and decrease mortality in patients with cirrhosis with and without ascites. Clinical Liver Disease 2022, 20: 1-4. PMID: 35899241, PMCID: PMC9306434, DOI: 10.1002/cld.1210.Peer-Reviewed Original ResearchAscites and its complications
Garcia‐Tsao G. Ascites and its complications. 2022, 522-531. DOI: 10.1002/9781119600527.ch59.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsCirrhotic ascitesPresence of ascitesMainstay of therapySevere liver diseaseSpontaneous bacterial peritonitisAccumulation of fluidHepatorenal syndromePeritoneal malignancyUncomplicated ascitesAbdominal ultrasonographySodium restrictionCirrhotic patientsHepatic hydrothoraxBacterial peritonitisHeart failureLiver diseaseDecompensated stageCommon causePeritoneal cavityAscitesPatientsMost cost-effective methodBacterial infectionsCirrhosisCommon typeAscites and its complications
García‐Tsao G. Ascites and its complications. 2022, 2024-2043. DOI: 10.1002/9781119600206.ch98.Peer-Reviewed Original ResearchHepatic sinusoidal pressureHepatic venous pressure gradientSerum-ascites albumin gradientAcute kidney injuryPresence of ascitesVenous pressure gradientMain pathogenic mechanismPredominance of neutrophilsSinusoidal pressureAccumulation of fluidAbdominal ultrasonographyKidney injurySodium restrictionCirrhotic patientsPortal pressureSodium retentionDecompensated stageInflammatory processPolymorphonuclear cellsPeritoneal cavityAscites albuminAscitic fluidAscitesCirrhosisPathogenic mechanisms
2021
Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases
Biggins SW, Angeli P, Garcia‐Tsao G, Ginès P, Ling SC, Nadim MK, Wong F, Kim WR. Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 2021, 74: 1014-1048. PMID: 33942342, DOI: 10.1002/hep.31884.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2020
Sodium‐Glucose Cotransporter 2 Inhibitors Ameliorate Ascites and Peripheral Edema in Patients With Cirrhosis and Diabetes
Montalvo‐Gordon I, Chi‐Cervera L, García‐Tsao G. Sodium‐Glucose Cotransporter 2 Inhibitors Ameliorate Ascites and Peripheral Edema in Patients With Cirrhosis and Diabetes. Hepatology 2020, 72: 1880-1882. PMID: 32294260, DOI: 10.1002/hep.31270.Peer-Reviewed Original ResearchSAT139 Safety, tolerability, pharmacokinetics and pharmacodynamic activity of terlipressin delivered by continuous intravenous infusion in patients with cirrhosis and refractory ascites: a phase 2a open-label trial
Bajaj J, Yeramian P, Gavis E, Fagan A, Fischer J, Garcia-Tsao G, Angeli P, Smith D, Adams J, Markham P. SAT139 Safety, tolerability, pharmacokinetics and pharmacodynamic activity of terlipressin delivered by continuous intravenous infusion in patients with cirrhosis and refractory ascites: a phase 2a open-label trial. Journal Of Hepatology 2020, 73: s718-s719. DOI: 10.1016/s0168-8278(20)31895-x.Peer-Reviewed Original Research
2019
Tu1519 – The Natural Histyory of Stages 2 & 3 Acute Kidney Injury (AKI) in Patients with Decompensated Cirrhosis and Ascites
Wong F, Reddy K, Tandon P, O'Leary J, Garcia-Tsao G, Lai J, Vargas H, Biggins S, Maliakkal B, Fallon M, Subramanian R, Thuluvath P, Kamath P, Thacker L, Bajaj J. Tu1519 – The Natural Histyory of Stages 2 & 3 Acute Kidney Injury (AKI) in Patients with Decompensated Cirrhosis and Ascites. Gastroenterology 2019, 156: s-1351. DOI: 10.1016/s0016-5085(19)40399-5.Peer-Reviewed Original ResearchSAT-140-The natural history of stages 2 and 3 acute kidney injury in hospitalized patients with decompensated cirrhosis and ascites
Wong F, Reddy R, Tandon P, O’leary J, Garcia-Tsao G, Lai J, Vargas H, Biggins S, Maliakkal B, Fallon M, Subramanian R, Thuluvath P, Kamath P, Thacker L, Bajaj J. SAT-140-The natural history of stages 2 and 3 acute kidney injury in hospitalized patients with decompensated cirrhosis and ascites. Journal Of Hepatology 2019, 70: e692. DOI: 10.1016/s0618-8278(19)31379-9.Peer-Reviewed Original Research
2018
Ascites
Garcia‐Tsao G. Ascites. 2018, 127-150. DOI: 10.1002/9781119237662.ch9.Peer-Reviewed Educational MaterialsLarge-volume paracentesesHepatorenal syndromeRefractory ascitesCirrhotic ascitesCommon decompensating eventMassive hepatic metastasesPlasma renin activitySecond-line treatmentFormation of ascitesDevelopment of ascitesCost-effective treatmentSinusoidal hypertensionCardiac indexRenin activityVasodilatory stateHepatic metastasesMalignant ascitesAscites formationCommon precipitantsAscitesHigh mortalityBacterial infectionsHyponatremiaMain predictorsPatients
2017
Beta‐blockers in hospitalised patients with cirrhosis and ascites: mortality and factors determining discontinuation and reinitiation
Bhutta A, Garcia‐Tsao G, Reddy K, Tandon P, Wong F, O'Leary J, Acharya C, Banerjee D, Abraldes J, Jones T, Shaw J, Deng Y, Ciarleglio M, Bajaj J. Beta‐blockers in hospitalised patients with cirrhosis and ascites: mortality and factors determining discontinuation and reinitiation. Alimentary Pharmacology & Therapeutics 2017, 47: 78-85. PMID: 28994122, PMCID: PMC6016372, DOI: 10.1111/apt.14366.Peer-Reviewed Original ResearchConceptsMean arterial pressureBeta-blocker useLower mean arterial pressureBeta-blocker discontinuationRefractory ascitesHigh mortalityLower white blood cell countBeneficial anti-inflammatory effectsWhite blood cell countAcute kidney injuryAnti-inflammatory effectsTime of discontinuationBlood cell countEffect of BBBB discontinuationKidney injuryChart reviewHospital dischargeArterial pressureDiscontinuationAscitesCirrhosisPatientsCell countMortalityChapter 36 Ascites
Garcia-Tsao G. Chapter 36 Ascites. 2017, 475-484. DOI: 10.1016/b978-0-12-804274-8.00036-9.Peer-Reviewed Educational MaterialsRefractory ascitesCommon decompensating eventNew-onset ascitesSodium-retaining systemsFirst-line therapyDevelopment of ascitesCause of deathPortal hypertensionRenal failureSodium retentionPathophysiological mechanismsOvert infectionAscitesPathogenic cascadeHigh mortalityVasodilatationEarly placementPatientsCirrhosisDeathHypertensionTherapyInfectionMortality
2016
Sa1645 Beta-Blocker (BB) Use in Hospitalized Cirrhotic Patients With Ascites Is Associated With a Lower MELD, Less Inflammation and an Improved Survival
Bhutta A, Garcia-Tsao G, Reddy K, Tandon P, Wong F, O'Leary J, Acharya C, Banerjee D, Abraldes J, Plener I, Jones T, Shaw J, Deng Y, Ciarleglio M, Bajaj J. Sa1645 Beta-Blocker (BB) Use in Hospitalized Cirrhotic Patients With Ascites Is Associated With a Lower MELD, Less Inflammation and an Improved Survival. Gastroenterology 2016, 150: s1084-s1085. DOI: 10.1016/s0016-5085(16)33659-9.Peer-Reviewed Original ResearchApproach to the Patient with Ascites and Its Complications
Garcia‐Tsao G. Approach to the Patient with Ascites and Its Complications. 2016, 447-458. DOI: 10.1002/9781118512104.ch55.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsLarge-volume paracentesisSpontaneous bacterial peritonitisNew-onset ascitesPresence of ascitesAcute renal failureFirst-line therapyMainstay of therapySerial large-volume paracentesisEtiology of ascitesAccumulation of fluidHepatorenal syndromePeritoneal malignancyAbdominal ultrasonographyRefractory ascitesSodium restrictionHepatic hydrothoraxLine therapyRenal failureBacterial peritonitisHeart failureDecompensated stageCirrhotic ascitesCommon causePeritoneal cavityAscitesEffect of Current Therapies Aimed at Preventing Variceal Rebleeding on Other Complications of Cirrhosis
Ripoll C, Augustin S, Reiberger T, Moreau R, Salerno F, Albillos A, Abraldes J, Garcia-Tsao G. Effect of Current Therapies Aimed at Preventing Variceal Rebleeding on Other Complications of Cirrhosis. 2016, 333-339. DOI: 10.1007/978-3-319-23018-4_33.Peer-Reviewed Original ResearchComplications of cirrhosisNon-bleeding complicationsNonselective beta blockersBeta blockersLower incidenceSecondary prophylaxisHepatic encephalopathyHepatocellular carcinomaBeneficial effectsLower dysfunction rateNon-hemodynamic effectsDysfunction rateVariceal bleedingCurrent therapiesCovered stentsHemodynamic responseBetter survivalComplicationsCirrhosisBlockersProphylaxisAscitesEarly TIPSIncidencePatientsSecondary Prophylaxis in Special Patient Populations
Reiberger T, Moreau R, Ripoll C, Albillos A, Augustin S, Salerno F, Abraldes J, Garcia-Tsao G. Secondary Prophylaxis in Special Patient Populations. 2016, 317-332. DOI: 10.1007/978-3-319-23018-4_32.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsSecondary prophylaxisRefractory ascitesVariceal bleedingSurvival benefitClinical nonrespondersClear precipitating eventProphylaxis of varicealBeta-blocker therapyBeta-blocker treatmentEndoscopic band ligationSpecial patient populationsAdvanced cirrhosisNSBB therapyVariceal rebleedingArterial hypotensionCirrhotic patientsFurther decompensationSerum creatinineBand ligationPatient populationProphylaxisHigh riskCurrent evidencePatientsAscitesTHU-001 Beta-Blocker Use in Hospitalized Cirrhotic Patients with Ascites is Associated with a Lower Meld, less Inflammation and an Improved Survival
Bhutta A, Garcia-Tsao G, Reddy R, Tandon P, Wong F, O’Leary J, Acharya C, Banerjee D, Abraldes J, Plener I, Jones T, Shaw J, Deng Y, Ciarleglio M, Bajaj J. THU-001 Beta-Blocker Use in Hospitalized Cirrhotic Patients with Ascites is Associated with a Lower Meld, less Inflammation and an Improved Survival. Journal Of Hepatology 2016, 64: s245. DOI: 10.1016/s0168-8278(16)00253-1.Peer-Reviewed Original Research
2015
Ascites and Its Complications
Garcia‐Tsao G. Ascites and Its Complications. 2015, 2087-2106. DOI: 10.1002/9781118512074.ch106.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsAcute kidney injuryHepatorenal syndromeCompatible clinical presentationPostliver transplant outcomesCause of ascitesPancreatic ductal systemAccumulation of fluidKidney injuryTransplant outcomesTuberculous peritonitisHeart failureClinical presentationPancreatic ascitesDecompensated stageMalignant ascitesCirrhosisPeritoneal cavityAscitesBetter survivalDuctal systemPatientsPancreatic fluidOptimal managementComplicationsMain causeCorrigendum to “Diagnosis and management of acute kidney injury in patients with cirrhosis: Revised consensus recommendations of the International Club of Ascites” [J Hepatol 2015;62:968–974]
Angeli P, Ginès P, Wong F, Bernardi M, Boyer T, Gerbes A, Moreau R, Jalan R, Sarin S, Piano S, Moore K, Lee S, Durand F, Salerno F, Caraceni P, Kim W, Arroyo V, Garcia-Tsao G. Corrigendum to “Diagnosis and management of acute kidney injury in patients with cirrhosis: Revised consensus recommendations of the International Club of Ascites” [J Hepatol 2015;62:968–974]. Journal Of Hepatology 2015, 63: 290. DOI: 10.1016/j.jhep.2015.04.001.Commentaries, Editorials and Letters